GH:NASDAQ, Guardant Health, Inc.
GH stock overview
Guardant Health, Inc. (GH:NASDAQ) closed at $162.99 on October 14, 2026,
up 0.56% on the day.
The stock trades 14.7% below its 52-week high of $191.05
and 158.8% above its 52-week low of $62.99.
Over the past year, it gained 153.9%.
Guardant Health, Inc. is part of the Health Care sector (Medical Specialities).
Key figures
- Price
- $162.99
- Day change
- +0.56%
- Volume
- 1,278,798
- Average volume
- 1,969,431
- Market cap
- 21B+
- 52-week range
- $62.99 – $191.05
- 50-day average
- $167.94
- 200-day average
- $126.35
Performance
| 5D |
1M |
3M |
6M |
1Y |
| +0.12% |
-7.21% |
+4.57% |
+78.97% |
+153.92% |
Price action over the past year
In 252 trading sessions since October 14, 2025, GH closed higher on 136 days (54%).
Its best day was October 30, 2025 (+27.87%) and its worst was April 10, 2026 (-9.83%).
The stock moved 10% or more in a single session 4 times.
It opened at least 5% above the previous day's high 2 times.
Recent signals
GH news
-
Oct 14, 2026:
Liquid Biopsy Market Research to Reach USD 27.42 Billion by 2035 as Cancer Blood Tests, AI Diagnostics and Precision Oncology Advance
-
Oct 9, 2026:
Grail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy?
-
Oct 9, 2026:
Could You Have Seen The Run In Tempus AI Stock Coming?
-
Oct 8, 2026:
Guardant Health Announces Approval in Europe of Guardant360 CDx as Companion Diagnostic for AstraZeneca's ETCAMAH (camizestrant) in Advanced ER-positive Breast Cancer
-
Oct 8, 2026:
Guardant Health Announces Approval in Europe of Guardant360® CDx as Companion Diagnostic for AstraZeneca's ETCAMAH™ (camizestrant) in Advanced ER-positive Breast Cancer
-
Oct 8, 2026:
Guardant Health to Report Third Quarter 2026 Financial Results on November 5, 2026
-
Oct 8, 2026:
Liquid Biopsy Market to Reach US$15.1 Billion by 2030 at 13.2% CAGR, Driven by Early Cancer Detection and Precision Medicine
-
Oct 7, 2026:
Dow Jones Futures Fall, Yields Rise After S&P 500 Hits High; Astera, GE Vernova, Arista Lead Buys
About Guardant Health, Inc.
Guardant Health Inc is a precision oncology company. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Geographically, the company generates a majority of its revenue from the United States.
Similar stocks
Find more stocks like GH with the
Spikes,
Gaps,
Breakouts and
Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.